In a clinical study involving five late-stage cancer patients, injection of αGC-loaded DCs led to the robust proliferation of iNKT cells, sustained IFN-γ secretion, and enhanced antigen-specific CD8+ T-cell expansion ex vivo, as compared to injection of unpulsed DCs (134, 135). The gene discussed is CD8A; the disease is cancer.